GSK‐3β inhibitor TDZD‐8 reduces neonatal hypoxic‐ischemic brain injury in mice

AIMS: Glycogen synthase kinase 3β (GSK‐3β) is activated following hypoxic‐ischemic (HI) brain injury. TDZD‐8 is a specific GSK‐3β inhibitor. Currently, the impact of inhibiting GSK‐3β in neonatal HI injury is unknown. We aimed to investigate the effect of TDZD‐8 following neonatal HI brain injury. M...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:CNS Neurosci Ther
Main Authors: Huang, Sammen, Wang, Haitao, Turlova, Ekaterina, Abussaud, Ahmed, Ji, Xiang, Britto, Luiz R., Miller, Steven P., Martinez, Ana, Sun, Hong‐Shuo, Feng, Zhong‐Ping
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6492674/
https://ncbi.nlm.nih.gov/pubmed/28256059
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.12683
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares